Page 8 - Bio Developments News Today

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and the Flow Cytometry Facility at the Babraham Institute have announced a collaboration to develop a bespoke cell phenotyping assay for human blood.

Stimulants, amphetamines, and methylphenidates are currently the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major global markets; France, Germany, Italy, Spain, the UK, the US, and Japan.

Biotechnology company Vaxxinity has announced its collaboration with the University of Central Florida (UCF) to advance space medicine research.

Abzena, an end-to-end CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms to accelerate cell lie production for manufacturing antibodies and recombinant proteins.

Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck.

The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical trial accounting for 81% of trials in 2023 and 80% in 2022.

Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.

TrakCel, a provider of cellular orchestration systems to the cell and gene therapy (CGT) industry, has launched its own consultancy services to share its process development knowledge with the broader community of CGT developers.

Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US.

Sexual health pharmaceutical company Futura Medical has extended its exclusive licensing agreement with Cooper Consumer Health for the rights to commercialize its topical, gel-based erectile dysfunction treatment.